Phodabra

Dabrafenib (Tafinlar) instructions

Common name: dabrafenib

Trade name: Tafinlar

Full names: dabrafenib, dabrafenib mesylate capsules, dabrafenib, Tafinlar

Dabrafenib indications:

Applicable to unresectable or metastatic BRAF Treatment of patients with V600E-mutated melanoma.

Dabrafenib reference usage and dosage:

The recommended dose of dabrafenib is 150 mg orally twice a day, dabrafenib as a single agent or in combination with trametinib 2 mg orally once a day. Take at least 1 hour before meals and at least 2 hours after meals

Adverse reactions of dabrafenib:

(1) The most common adverse reactions (≥20%) of dabrafenib as a single agent are hyperkeratosis, headache, fever, arthritis, papilloma, alopecia, and palmoplantar erythrodysesthesia and pain syndrome.

(2) The most common adverse reactions (≥20%) of dabrafenib in combination with trametinib include fever, chills, fatigue, rash, nausea, vomiting, diarrhea, abdominal pain, peripheral edema, cough, headache, arthralgia, night sweats, decreased appetite, constipation, and myalgia.

Dabrafenib Precautions:

New primary cutaneous malignancies: Perform dermatologic evaluation prior to initiating treatment, every 3 months during treatment and up to 6 months after discontinuation of TAFINLAR.

Tumor promotion in BRAF wild-type melanoma: Increased cell proliferation may occur with BRAF inhibitors.

Severe febrile drug reactions: Do not use TAFINLAR if fever ≥101.3°F or concurrent fever occurs.

Hyperglycemia: Monitor serum glucose levels in patients with pre-existing diabetes or hyperglycemia.

Uveitis and iritis: Routinely monitor patients for visual symptoms.

Glucose-6-phosphate dehydrogenase deficiency: Monitor closely for hemolytic anemia.

Embryo-fetal toxicity: May cause fetal harm. Advise females of reproductive potential of the potential risk to the fetus. TAFINLAR may make hormonal contraceptives less effective and an alternative method of contraception should be used.